People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Biotechnology, Software / Tech, Other Technology, Edtech, Other Health Care, Other Energy
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxxinity, Inc. | — | Biotechnology | Growth/Late | $1.4B | $927.3M | 2021 |
| Hyperloop Technologies, Inc. | — | Software / Tech | Series D+ | $299.9M | $5.4B | 2014 |
| Celularity Inc. | — | Biotechnology | Series C | $117.7M | $3.2B | 2018 |
| Planetary Resources, Inc. | — | Other Technology | Series B | $34.8M | $1.1B | 2015 |
| C19 Corp. | — | Biotechnology | Series B | $32.9M | $684.4M | 2020 |
| Singularity Education Group | — | Edtech | Series B | $22.5M | $386.7M | 2015 |
| Fountain Life Holdings, LLC | — | Other Health Care | Series A | $17.1M | $238.4M | 2021 |
| Lifeforce Digital Inc. | — | Software / Tech | Series A | $5.5M | $80.2M | 2022 |
| Planetary Power, Inc. | — | Other Energy | Seed | $2.0M | $26.5M | 2015 |
| MK Stem Cell Inc. | — | Biotechnology | Pre-Seed | $700K | $22.1M | 2015 |
PETER DIAMANDIS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside PETER DIAMANDIS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eric Anderson | 2 | 11 |
| Dakin Sloss | 2 | 9 |
| Mei Mei Hu | 2 | 2 |
| JOSEPH LANDON | 2 | 2 |
| Louis Reese | 2 | 2 |
| Ray Kurzweil | 2 | 2 |
| Erik Anderson | 1 | 12 |
| DAVID SACKS | 1 | 12 |
| Shervin Pishevar | 1 | 8 |
| Joe Lonsdale | 1 | 8 |
| Michael Murray | 1 | 7 |
| John Sculley | 1 | 6 |
| Henry Ji | 1 | 5 |
| Robert Hariri | 1 | 5 |
| NAVEEN JAIN | 1 | 5 |
| BRIAN CARROLL | 1 | 5 |
| Courtney Reum | 1 | 5 |
| Timothy Smith | 1 | 5 |
| Tim Smith | 1 | 4 |
| Andrew Pecora | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.